K R Frazier1, J A Moore1, T E Long1,2. 1. Department of Pharmaceutical Science and Research, School of Pharmacy, Marshall University, Huntington, WV, USA. 2. Department of Biomedical Sciences, Joan C. Edwards School of Medicine, Marshall University, Huntington, WV, USA.
Abstract
AIMS: Disulfiram (Antabuse™) and its metabolites formed in vivo were evaluated as antibacterial agents against thirty species of Gram-positive and Gram-negative bacteria. The synergistic potential of disulfiram (DSF) and metabolite diethyldithiocarbamate (DDTC) with approved antibiotics were also compared by isobologram (checkerboard) analysis. METHODS AND RESULTS: Standard microdilution susceptibility testing showed that most DSF metabolites did not possess appreciable antibacterial activity except for DDTC in Bacillus anthracis. Checkerboard studies revealed similarities between the combination drug effects of DSF and DDTC with standard antibiotics. CONCLUSIONS: It was concluded from the susceptibility data that the metabolites would not extend the antibacterial spectrum of DSF in vivo. The data also suggest that the DDTC by-product of DSF metabolism potentiates the antibacterial activity of DSF as both a standalone and combination agent. SIGNIFICANCE AND IMPACT OF THE STUDY: The study provides a greater understanding of the antibacterial effects of Antabuse and its metabolites. This research also demonstrates the potential application of DSF as an antibiotic adjuvant for the treatment of resistant staph infections.
AIMS: Disulfiram (Antabuse™) and its metabolites formed in vivo were evaluated as antibacterial agents against thirty species of Gram-positive and Gram-negative bacteria. The synergistic potential of disulfiram (DSF) and metabolite diethyldithiocarbamate (DDTC) with approved antibiotics were also compared by isobologram (checkerboard) analysis. METHODS AND RESULTS: Standard microdilution susceptibility testing showed that most DSF metabolites did not possess appreciable antibacterial activity except for DDTC in Bacillus anthracis. Checkerboard studies revealed similarities between the combination drug effects of DSF and DDTC with standard antibiotics. CONCLUSIONS: It was concluded from the susceptibility data that the metabolites would not extend the antibacterial spectrum of DSF in vivo. The data also suggest that the DDTC by-product of DSF metabolism potentiates the antibacterial activity of DSF as both a standalone and combination agent. SIGNIFICANCE AND IMPACT OF THE STUDY: The study provides a greater understanding of the antibacterial effects of Antabuse and its metabolites. This research also demonstrates the potential application of DSF as an antibiotic adjuvant for the treatment of resistant staph infections.
Authors: Laurine Kaul; Adrian I Abdo; Tom Coenye; Bastiaan P Krom; Michel A Hoogenkamp; Andrew C W Zannettino; Regine Süss; Katharina Richter Journal: Front Microbiol Date: 2022-09-09 Impact factor: 6.064
Authors: Federico Serral; Florencia A Castello; Ezequiel J Sosa; Agustín M Pardo; Miranda Clara Palumbo; Carlos Modenutti; María Mercedes Palomino; Alberto Lazarowski; Jerónimo Auzmendi; Pablo Ivan P Ramos; Marisa F Nicolás; Adrián G Turjanski; Marcelo A Martí; Darío Fernández Do Porto Journal: Front Pharmacol Date: 2021-06-09 Impact factor: 5.810
Authors: Alexandria D Lewis; Taylor M Riedel; Meredith B A Kesler; Melinda E Varney; Timothy E Long Journal: J Antibiot (Tokyo) Date: 2022-01-20 Impact factor: 3.424